{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:06:14Z","timestamp":1775106374030,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01707-z","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:20:07Z","timestamp":1772511607000},"page":"1841-1845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-Dose,\u00a0Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"1","key":"1707_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Duffin KC, Huang YH, Savage LJ, Guo L, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45.","journal-title":"Nat Rev Dis Primers"},{"key":"1707_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67475-0","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Jiang R, Shi L, Tsoi LC, Bogle R, Fox J, et al. A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-67475-0.","journal-title":"Nat Commun"},{"key":"1707_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, et al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160:e242463. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2463.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1707_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40257-024-00894-9","volume":"25","author":"M Luz","year":"2024","unstructured":"Luz M, Torres T. Real-world evidence on dose spacing of IL-23 inhibitors in the treatment of psoriasis. Am J Clin Dermatol. 2024;25(6):1019\u201321.","journal-title":"Am J Clin Dermatol"},{"key":"1707_CR5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.18787","volume":"37","author":"L Iversen","year":"2023","unstructured":"Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate-to-severe plaque psoriasis patients: week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37:1004\u201316. https:\/\/doi.org\/10.1111\/jdv.18787.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1707_CR6","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19072","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u201cclinical super response\u201d): week 28 results from the GUIDE study. J Eur Acad Dermatol Venereol. 2023;37:2016\u201327. https:\/\/doi.org\/10.1111\/jdv.19072.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 3","key":"1707_CR7","doi-asserted-by":"publisher","first-page":"ljae360.075","DOI":"10.1093\/bjd\/ljae360.075","volume":"191","author":"K Sch\u00e4kel","year":"2024","unstructured":"Sch\u00e4kel K, Asadullah K, Pinter A, Weisenseel P, Sabat R, Hoffmann M, et al. Long-term remission after guselkumab withdrawal in patients treated within 15 months from symptom onset: GUIDE trial part 3. Br J Dermatol. 2024;191(Suppl 3):ljae360.075. https:\/\/doi.org\/10.1093\/bjd\/ljae360.075.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1707_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40257-025-00949-5","volume":"26","author":"D Ranzinger","year":"2025","unstructured":"Ranzinger D, Eyerich K. Disease modification in psoriasis: future prospects for long-term remission. Am J Clin Dermatol. 2025;26(4):477\u201386. https:\/\/doi.org\/10.1007\/s40257-025-00949-5.","journal-title":"Am J Clin Dermatol"},{"key":"1707_CR9","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1172\/JCI93396","volume":"127","author":"TR Matos","year":"2017","unstructured":"Matos TR, O\u2019Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17\u2013producing \u03b1\u03b2 T cell clones. J Clin Invest. 2017;127:4031\u201341. https:\/\/doi.org\/10.1172\/JCI93396.","journal-title":"J Clin Invest"},{"issue":"9","key":"1707_CR10","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1111\/jdv.18176","volume":"36","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Maurelli M, Bellinato F, Girolomoni G. Is risankizumab as-needed administration a good option for patients with plaque psoriasis? J Eur Acad Dermatol Venereol. 2022;36(9):e713\u20135. https:\/\/doi.org\/10.1111\/jdv.18176.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1707_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","volume":"136","author":"JG Krueger","year":"2015","unstructured":"Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, et al. Anti\u2013IL-23A monoclonal antibody BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results. J Allergy Clin Immunol. 2015;136(1):116-124.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"1707_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf213","author":"L Peyrin-Biroulet","year":"2025","unstructured":"Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, et al. Efficacy and safety of risankizumab in patients with moderately to severely active Crohn\u2019s disease: interim results from the SEQUENCE open-label extension study. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf213.","journal-title":"J Crohns Colitis"},{"key":"1707_CR13","doi-asserted-by":"crossref","unstructured":"Krueger J. Phase 1 clinical data of ORKA-001, a novel half-life\u2013extended IL-23p19 monoclonal antibody with potential for once-yearly dosing in plaque psoriasis. Presented at European Academy of Dermatology and Venereology (EADV) Congress; September 18, 2025; Paris, France. Late-breaking oral presentation. Abstract D2T01.4D.","DOI":"10.25251\/w0x98v10"},{"key":"1707_CR14","doi-asserted-by":"crossref","unstructured":"Blauvelt A. EVERLAST-A: a phase 2a study design of ORKA-001, a novel half-life\u2013extended IL-23p19 monoclonal antibody for plaque psoriasis. Presented at European Academy of Dermatology and Venereology (EADV) Congress; September 18, 2025; Paris, France. Oral presentation. Abstract FC02.1.","DOI":"10.25251\/jg65bt44"},{"key":"1707_CR15","unstructured":"Spyre Therapeutics. Spyre Therapeutics announces positive interim phase 1 results for SPY003. 2024. https:\/\/ir.spyre.com\/news-releases\/news-release-details\/spyre-therapeutics-announces-positive-interim-phase-1-results-0. Accessed 18 Feb 2026."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01707-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01707-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01707-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:31Z","timestamp":1775101111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01707-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1707"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01707-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiago Torres: speaker, scientific adviser, and clinical study investigator for AbbVie, Almirall, Amgen, Apogee, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Johnson and Johnson, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. Tiago Torres is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Andrew Blauvelt: speaker (received honoraria) for Almirall, Eli Lilly, Leo, Sanofi, and UCB, scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Eli Lilly, Incyte, Janssen, Leo, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB and stock owner in Lipidio and Oruka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}